Cargando…
Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
INTRODUCTION: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk. MATERIAL AND METHODS: Eligible case-co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212224/ https://www.ncbi.nlm.nih.gov/pubmed/32399118 http://dx.doi.org/10.5114/aoms.2020.94657 |
_version_ | 1783531579842232320 |
---|---|
author | Yuan, Cunzhong Liu, Xiaoyan Li, Rongrong Yan, Shi Kong, Beihua |
author_facet | Yuan, Cunzhong Liu, Xiaoyan Li, Rongrong Yan, Shi Kong, Beihua |
author_sort | Yuan, Cunzhong |
collection | PubMed |
description | INTRODUCTION: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk. MATERIAL AND METHODS: Eligible case-control studies were searched in PubMed. We therefore performed a meta-analysis of 5,802 ovarian cancer cases and 9,390 controls from 7 articles published. The strength of association between XRCC2 rs3218536 polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). RESULTS: No statistically significant associations between XRCC2 rs3218536 polymorphism and ovarian cancer risk were found in any genetic models. However, a significant relationship with ovarian cancer risk was discovered when the high quality studies were pooled in the meta-analysis (AA vs. GG: OR = 0.59, 95% CI: 0.37–0.94, p = 0.03; GA vs. GG: OR = 0.87, 95% CI: 0.78–0.96, p = 0.009; GA + AA vs. GG: OR = 0.85, 95% CI: 0.77–0.94, p = 0.003; AA vs. GG + GA: OR = 0.60, 95% CI: 0.38–0.95, p = 0.03). CONCLUSIONS: This meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with ovarian cancer risk overall for high quality studies. Non-Caucasian groups and high quality studies should be further studied. |
format | Online Article Text |
id | pubmed-7212224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-72122242020-05-12 Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk Yuan, Cunzhong Liu, Xiaoyan Li, Rongrong Yan, Shi Kong, Beihua Arch Med Sci Basic Research INTRODUCTION: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk. MATERIAL AND METHODS: Eligible case-control studies were searched in PubMed. We therefore performed a meta-analysis of 5,802 ovarian cancer cases and 9,390 controls from 7 articles published. The strength of association between XRCC2 rs3218536 polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). RESULTS: No statistically significant associations between XRCC2 rs3218536 polymorphism and ovarian cancer risk were found in any genetic models. However, a significant relationship with ovarian cancer risk was discovered when the high quality studies were pooled in the meta-analysis (AA vs. GG: OR = 0.59, 95% CI: 0.37–0.94, p = 0.03; GA vs. GG: OR = 0.87, 95% CI: 0.78–0.96, p = 0.009; GA + AA vs. GG: OR = 0.85, 95% CI: 0.77–0.94, p = 0.003; AA vs. GG + GA: OR = 0.60, 95% CI: 0.38–0.95, p = 0.03). CONCLUSIONS: This meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with ovarian cancer risk overall for high quality studies. Non-Caucasian groups and high quality studies should be further studied. Termedia Publishing House 2020-04-25 /pmc/articles/PMC7212224/ /pubmed/32399118 http://dx.doi.org/10.5114/aoms.2020.94657 Text en Copyright: © 2019 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Basic Research Yuan, Cunzhong Liu, Xiaoyan Li, Rongrong Yan, Shi Kong, Beihua Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk |
title | Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk |
title_full | Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk |
title_fullStr | Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk |
title_full_unstemmed | Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk |
title_short | Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk |
title_sort | analysis of the association between the xrcc2 rs3218536 polymorphism and ovarian cancer risk |
topic | Basic Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212224/ https://www.ncbi.nlm.nih.gov/pubmed/32399118 http://dx.doi.org/10.5114/aoms.2020.94657 |
work_keys_str_mv | AT yuancunzhong analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk AT liuxiaoyan analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk AT lirongrong analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk AT yanshi analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk AT kongbeihua analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk |